Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03511196 · ClinicalTrials.gov registry record · Early Phase 1
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
A Early Phase 1 study of Prostate Cancer and Stage IV Prostate Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT03511196: Active Early Phase 1 study of Prostate Cancer and Stage IV Prostate Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT03511196 is a Early Phase 1 study of Prostate Cancer and Stage IV Prostate Cancer that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 17 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03511196, a Early Phase 1 study of Prostate Cancer and Stage IV Prostate Cancer, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
Adaptive Androgen Deprivation Therapy (ADT) plus Standard of Care. The purpose of this study is to develop adaptive therapy for high risk metastatic castration sensitive prostate cancer (mCSPC).
Primary Outcome
Percentage of participants who remain on study at month 12. The study will be terminated early if 2 or more of the first 6 enrolled subjects discontinued study due to cancer progression within a year of study enrollment.
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Abiraterone
- DRUG Adaptive Androgen Deprivation Therapy (ADT)
Study Locations (1)
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2026-09 |
| Phase | Early Phase 1 |
What the registry record for NCT03511196 still lists
NCT03511196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Prednisone is the first listed.
NCT03511196 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03511196 about?
NCT03511196 is a clinical study titled "Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer". Adaptive Androgen Deprivation Therapy (ADT) plus Standard of Care. The purpose of this study is to develop adaptive therapy for high risk metastatic castration sensitive prostate cancer (mCSPC).
What is the current status of trial NCT03511196?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2018-09-17. Estimated completion is 2026-09.
What conditions does trial NCT03511196 study?
This clinical trial studies the following conditions: Prostate Cancer, Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Advanced Prostate Cancer.
What interventions are being tested in trial NCT03511196?
The interventions under investigation include: Prednisone (DRUG), Abiraterone (DRUG), Adaptive Androgen Deprivation Therapy (ADT) (DRUG).
Who is sponsoring clinical trial NCT03511196?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03511196 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03511196's enrollment target sits among peer trials
17 681st of 735 higher than 54 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
RECRUITING · Early Phase 1
-
Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
RECRUITING · Early Phase 1
-
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
RECRUITING · Early Phase 1
-
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
RECRUITING · Early Phase 1
-
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
RECRUITING · Early Phase 1
-
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI